Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Genet ; 47(4): 230-5, 2010 Apr.
Article in English | MEDLINE | ID: mdl-19762328

ABSTRACT

BACKGROUND: Ostium secundum atrial septal defects (ASDII) account for approximately 10% of all congenital heart defects (CHD), and mutations in cardiac transcription factors, including TBX20, were identified as an underlying cause for ASDII. However, very little is known about disease penetrance in families and functional consequences of inherited TBX20 mutations. METHODS: The coding region of TBX20 was directly sequenced in 170 ASDII patients. Functional consequences of one novel mutation were investigated by surface plasmon resonance, CD spectropolarymetry, fluorescence spectrophotometry, luciferase assay and chromatin immunoprecipitation. RESULTS: We found a novel mutation in a highly conserved residue in the T-box DNA binding domain (I121M) segregating with CHD in a three generation kindred. Four mutation carriers revealed cardiac phenotypes in terms of cribriform ASDII, large patent foramen ovale or cardiac valve defects. Interestingly, tertiary hydrophobic interactions within the mutant TBX20 T-box were significantly altered leading to a more dynamic structure of the protein. Moreover, Tbx20-I121M resulted in a significantly enhanced transcriptional activity, which was further increased in the presence of co-transcription factors GATA4/5 and NKX2-5. Occupancy of DNA binding sites on target genes was also increased. CONCLUSIONS: We suggest that TBX20-I121M adopts a more fluid tertiary structure leading to enhanced interactions with cofactors and more stable transcriptional complexes on target DNA sequences. Our data, combined with that of others, suggest that human ASDII may be related to loss-of-function as well as gain-of-function TBX20 mutations.


Subject(s)
Foramen Ovale, Patent/genetics , Heart Septal Defects, Atrial/genetics , Heart Valves/abnormalities , Mutation , T-Box Domain Proteins/genetics , Adolescent , Animals , Base Sequence , COS Cells , Case-Control Studies , Chlorocebus aethiops , Chromatin Immunoprecipitation , Circular Dichroism , DNA/genetics , DNA/metabolism , Female , Foramen Ovale, Patent/metabolism , Heart Septal Defects, Atrial/metabolism , Humans , Male , Models, Molecular , Molecular Sequence Data , Pedigree , Sequence Alignment , Structural Homology, Protein , T-Box Domain Proteins/metabolism , Transcriptional Activation
2.
PLoS One ; 4(8): e6743, 2009 Aug 25.
Article in English | MEDLINE | ID: mdl-19707545

ABSTRACT

Connective tissue growth factor (CTGF) is a secreted protein that is strongly induced in human and experimental heart failure. CTGF is said to be profibrotic; however, the precise function of CTGF is unclear. We generated transgenic mice and rats with cardiomyocyte-specific CTGF overexpression (CTGF-TG). To investigate CTGF as a fibrosis inducer, we performed morphological and gene expression analyses of CTGF-TG mice and rat hearts under basal conditions and after stimulation with angiotensin II (Ang II) or isoproterenol, respectively. Surprisingly, cardiac tissues of both models did not show increased fibrosis or enhanced gene expression of fibrotic markers. In contrast to controls, Ang II treated CTGF-TG mice displayed preserved cardiac function. However, CTGF-TG mice developed age-dependent cardiac dysfunction at the age of 7 months. CTGF related heart failure was associated with Akt and JNK activation, but not with the induction of natriuretic peptides. Furthermore, cardiomyocytes from CTGF-TG mice showed unaffected cellular contractility and an increased Ca(2+) reuptake from sarcoplasmatic reticulum. In an ischemia/reperfusion model CTGF-TG hearts did not differ from controls.Our data suggest that CTGF itself does not induce cardiac fibrosis. Moreover, it is involved in hypertrophy induction and cellular remodeling depending on the cardiac stress stimulus. Our new transgenic animals are valuable models for reconsideration of CTGF's profibrotic function in the heart.


Subject(s)
Cardiomegaly/prevention & control , Connective Tissue Growth Factor/metabolism , Myocardium/cytology , Angiotensin II/administration & dosage , Animals , Base Sequence , Calcium/metabolism , Cardiomegaly/genetics , Cardiomegaly/physiopathology , Connective Tissue Growth Factor/genetics , DNA Primers , Enzyme Activation , Humans , Isoproterenol/administration & dosage , MAP Kinase Kinase 4/metabolism , Mice , Mice, Transgenic , Myocardial Ischemia/metabolism , Polymerase Chain Reaction , Pressure , Proto-Oncogene Proteins c-akt/metabolism , Rats
SELECTION OF CITATIONS
SEARCH DETAIL
...